We are live on ! Find out more
AEMD icon

Aethlon Medical

13 hedge funds and large institutions have $431K invested in Aethlon Medical in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1313 (0)

0% less ownership

Funds ownership: 0%0% (-0%)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

29% less capital invested

Capital invested by funds: $604K → $431K (-$173K)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
13
Holders Change
Holders Change %
0%
% of All Funds
0.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
2
Reduced
3
Closed
2
Calls
Puts
Net Calls
Net Calls Change

AEMD Hedge Fund Activity: Q3 2020 in Review

13 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Aethlon Medical (AEMD) for Q3 2020, worth a combined $431K — down 29% from $604K a quarter earlier.

Fund positioning in AEMD was balanced in Q3 2020: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $46K. The largest seller was Jane Street, exiting entirely with an estimated $34K sold.

  • 13 institutional investors held Aethlon Medical (AEMD) as of Q3 2020, unchanged from Q2 2020.
  • Funds reported $431K of Aethlon Medical stock for Q3 2020, down 29% quarter-over-quarter.
  • 2 funds opened new Aethlon Medical positions in Q3 2020 and 2 closed out, a net change of 0 holders.
  • The largest Aethlon Medical buyer in Q3 2020 was Renaissance Technologies, an estimated $46K added.
  • The largest Aethlon Medical seller in Q3 2020 was Jane Street, an estimated $34K sold.

Based on aggregated 13F filings for Q3 2020.